Barcelona

• A Study of Disitamab Vedotin Alone or with Pembrolizumab in Urothelial Cancer That Expresses HER2 Recruiting
  2022-500030-28-01 4 2024-06-10 Urothelial carcinoma
• BEAMION Lung-2: A study to test whether zongertinib (BI 1810631) helps people with advanced non-small cell lung cancer with HER2 mutations c … Recruiting
  2023-504308-27-00 5 2024-06-06 non-squamous non-small cell lung cancer
• [18F]PSMA-1007 PET CT in patients with newly-diagnosed prostate cancer Recruiting
  2023-504026-19-01 5 2024-06-05 Prostate Cancer
• A Phase 1b/2 Study of JNJ-90014496 in Adult Participants with B-cell Non-Hodgkin Lymphoma Recruiting
  2023-506267-33-00 3 2024-05-29 Non-Hodgkin Lymphoid Malignancies
• Efficacy and Safety of Patidegib Gel 2% for Preventing Basal Cell Carcinomas on the Face of Adults With Gorlin Syndrome Recruiting
  2023-507528-21-00 5 2024-05-23 Gorlin Syndrome
• An Open-label Study of Povetacicept in Subjects With Autoimmune Cytopenias (RUBY-4) Recruiting
  2023-507067-19-00 4 2024-05-15 Autoimmune Cytopenias (warm autoimmune hemolytic anemia [wAIHA], cold
• Long Term Study of Ecopipam Tablets in Children, Adolescents and Adults with Tourette’s Disorder Recruiting
  2023-503545-67-00 5 2024-04-30 Tourette's Disorder
• A phase I, multicentre, open-label, dose escalation study to determine the safety and preliminary efficacy of MBS8(1V270) administered intra … Recruiting
  2024-512294-26-00 1 2024-04-10 Advanced solid tumors
• CAR-T-cell treatment for untreated high risk MANtle Cell Lymphoma Recruiting
  2022-502405-15-01 4 2024-04-08 Mantle Cell Lymphoma (MCL)
• Dexamethasone for treating severe hospital-acquired pneumonia in critically ill patients with a proinflammatory phenotype, an international … Recruiting
  2023-508153-12-00 5 2024-03-26 Hospital-acquired pneumonia
• A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the E … Recruiting
  2023-507039-39-00 5 2024-03-22 Moderate to Severe Plaque Psoriasis
• A Study to Assess the Long-Term Safety and Efficacy of Lebrikizumab in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Ato … Recruiting
  2022-501478-21-00 5 2024-03-15 Atopic Dermatitis Eczema
• A Phase 1 Study of JNJ-87801493 in Combination with CD3 T-Cell Engagers Recruiting
  2023-505165-93-00 1 2024-03-01 Non-Hodgkin Lymphoid Malignancies
• A First-in-Human Study of ABBV-525 (MALT1 Inhibitor) in B-Cell Malignancies Recruiting
  2022-503136-13-00 1 2024-02-29 various B-cell malignancies
• Trial of Two Adagrasib Dosing Regimens in NSCLC with KRAS G12C Mutation Recruiting
  2023-503523-25-00 4 2024-02-29 Non-small cell lung cancer
• Open-Label Extension of EDG-5506 in Participants with Becker Muscular Dystrophy Recruiting
  2023-506231-15-00 4 2024-02-22 Becker Muscular Dystrophy
• Mirvetuximab soravtansine in combination with bevacizumab for the maintenance treatment of adult patients with FRα-high recurrent platinum-s … Recruiting
  2022-501606-35-01 11 2024-02-21 Platinum-sensitive epithelial ovarian, fallopian tube, or primary peri
• A phase 2b, randomized, double-blind study of redasemtide (S-005151) in adult participants with acute ischemic stroke Recruiting
  2022-501890-38-00 4 2024-02-16 acute ischemic stroke
• Early Sedation with Dexmedetomidine vs. Placebo in Older Ventilated Critically Ill Patients Recruiting
  2022-501157-36-00 6 2024-02-07 Critically ill patients who are dependent on high level medical care i
• A Study of Repotrectinib versus Crizotinib in Participants with Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-po … Recruiting
  2023-505604-32-00 5 2024-01-24 Non small cell lung cancer (NSCLC)
• A trial to learn if odronextamab is safe and well-tolerated and how well it works compared to rituximab combined with different types of che … Recruiting
  2022-502660-20-00 5 2024-01-23 Follicular lymphoma
• A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the E … Recruiting
  2023-505121-14-00 5 2024-01-18 Moderate to Severe Plaque Psoriasis
• Evaluation of the efficacy and safety of eneboparatide (AZP-3601) in patients with chronic hypoparathyroidism (CALYPSO) Recruiting
  2022-503126-12-01 5 2024-01-05 Hypoparathyroidism
• A Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Participants With Locally Advanced, Unresectable, Stage III N … Recruiting
  2023-503920-14-00 5 2024-01-02 Non-Small Cell Lung Cancer (NSCLC)

Showing 529–552 of 3,391 trials